Gamma retinoic acid receptor
AssigneesThe Salk Institute for Biological Studies, Sloan-Kettering Institute for Cancer Research
InventorsFumimaro Takaku, Takashi Ishikawa, Michio Imawari, Ronald Mark Evans, Kazuhiko Umesono
Life of this patent
Estimating the term…
Abstract
A novel gamma retinoic acid receptor is disclosed. The novel receptor is encoded for by cDNA carried on plasmid pGEM-hRARγ, which has been deposited with the American Type Culture Collection for patent purposes. Chimeric receptor proteins are also disclosed. The chimera contain at least one functional domain from the new gamma retinoic acid receptor.
Claims14
A substantially pure double-stranded DNA wherein the sense strand encodes the primary sequence of a protein which has ligand-binding and transcription-activating properties characteristic of gamma retinoic acid receptor protein.
The plasmid pGEM-hRARγ (ATCC No. 40623).
A substantially pure DNA sequence having substantial sequence homology with the DNA (hRARγ) of plasmid pGEM-hRARγ (ATCC No. 40623).
A substantially pure DNA segment which has (a) one triplet corresponding to a translation stop codon, which is in frame with a triplet corresponding to a translation start codon and downstream of said start codon triplet, and (b) as longest open reading frame, a substantially pure segment with a sequence of triplets encoding the primary sequence of gamma retinoic acid receptor protein.
A substantially pure DNA encoding human gamma retinoic acid receptor.
A substantially pure mRNA transcribed from any of the substantially pure DNA sequences claimed in any of claims of 1-9.
A substantially pure protein wherein the amino acid sequence comprising the DNA binding domain has at least about 98% homology with the amino acid sequence shown in FIG. 1.
Chimeric receptors having an N-termimus domain, a DNA-binding domain, and a ligand-binding domain wherein at least one of the domains is selected from the group consisting of the RARγ N-terminus domain, the RARγ DNA-binding domain, and the RARγ ligand-binding domain, and at least one of the remaining domains is selected from the group consisting of N-terminus, DNA-binding and ligand-binding domains from the glucocorticoid receptor, the mineralocorticoid receptor, the progesterone receptor, the estrogen receptor, the steroid-related receptors (ERR1 and ERR2), the vitamin D3 receptor, the thyroid receptors, the V-erb-A receptor, the E75 (Drosophilia) receptor, and the retinoic acid receptors alpha and beta.
Dependencies are inferred from the claim text.